Updated data show promise of targeted therapy in Castleman disease
David C. Fajgenbaum, a Penn Medicine researcher and Castleman disease patient, and his team demonstrated that there is increased activation of a specific pathway called PI3K/Akt/mTOR. The findings suggest that Castleman patients who do not respond to the only drug currently approved by the U.S. Food and Drug Administration for the treatment of the disease may have another option that targets this specific pathway.
FULL STORY AT Penn Medicine News →